Population pharmacokinetic analysis of letermovir in adult hematopoietic cell transplant recipients
We analyzed previously reported oral letermovir plasma concentration measurements from 40 allogeneic hematopoietic cell transplant (HCT) recipients using model-based pharmacometrics analysis. This analysis highlighted that the industry-sponsored phase III study model significantly over-predicted observed letermovir concentrations. Covariates associated with increased oral clearance (CL/F), possibly contributing to this observation, included: higher weight, younger age, and early use after HCT. The clinical significance and mechanistic explanation of relatively lower real-world exposure remains to be elucidated.
Authors
- Léna Royston (ORCID: https://orcid.org/0000-0003-2367-7682)
- Dionysios Neofytos (ORCID: https://orcid.org/0000-0001-6970-2869)
- Pierre Lescuyer (ORCID: https://orcid.org/0000-0001-6986-8738)
- Verena Gotta (ORCID: https://orcid.org/0000-0001-6254-5207)
- Christoph Kunz
- David Tonoli (ORCID: https://orcid.org/0000-0002-0988-9390)
Institutions
- University of Basel (CH)
- University Hospital of Geneva (CH)
- University Children’s Hospital Basel (CH)
- Geneva College (US)
Publication Details
- Journal
- Antimicrobial Agents and Chemotherapy
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1128/aac.00697-25
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung